Press Room

RDD 2022

Start
Monday, April 25, 2022 - 00:00
End
Thursday, June 30, 2022 - 00:00
Location: Florida, USA
Booth Number: Table 11
Hovione present at RDD 2022 | The specialist integrated CDMO

If you would like to find more about Hovione's full range of inhalation development servicesparticle engineering and development by design schedule a meeting with us.

 

Our experts are available to listen and understand your projects. Together we can speed up your Inhalation drug development, with less regulatory hurdles, less time, and less costs.

  

 
Drug Product Facility in Portugal | Hovione

Hovione Inhalation Development Virtual Tour (click on the image to watch video)

Meet Eunice Costa, Hovione’s group leader for Inhalation Development and visit the site where all the team sits together.

 

 

Schedule a meeting button | Hovione

 

 

 

 

Find more about Respiratory Drug Delivery 2022 (RDD 2022)

 

 

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026